Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (731-740 of 831) with videos related to

Pageof 84
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2015
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR TrialMichael Weller, Ghazaleh Tabatabai, Bärbel Kästner, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Designing Clinical Trials for Combination Immunotherapy: A Framework for GlioblastomaKirit Singh, Kristen A Batich, Patrick Y Wen, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
The Lancet. Digital Health|October 24, 2021
Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort studyChandrakanth Jayachandran Preetha, Hagen Meredig, Gianluca Brugnara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
JAMA|December 21, 2017
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew Kanner, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Journal for Immunotherapy of Cancer|April 16, 2021
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapyAna Marcu, Leon Bichmann, Leon Kuchenbecker, et al.
Neuro-Oncology|November 22, 2024
European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selectionFelix Sahm, Luca Bertero, Sebastian Brandner, et al.
Pageof 84

Showing results (731-740 of 831) with videos related to

Sort By:
Pageof 84
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2015
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR TrialMichael Weller, Ghazaleh Tabatabai, Bärbel Kästner, et al.
Neuro-Oncology|June 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Martin J van den Bent, Pim J French, Daniel Brat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Designing Clinical Trials for Combination Immunotherapy: A Framework for GlioblastomaKirit Singh, Kristen A Batich, Patrick Y Wen, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
The Lancet. Digital Health|October 24, 2021
Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort studyChandrakanth Jayachandran Preetha, Hagen Meredig, Gianluca Brugnara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
JAMA|December 21, 2017
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew Kanner, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Journal for Immunotherapy of Cancer|April 16, 2021
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapyAna Marcu, Leon Bichmann, Leon Kuchenbecker, et al.
Neuro-Oncology|November 22, 2024
European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selectionFelix Sahm, Luca Bertero, Sebastian Brandner, et al.
Pageof 84